2020
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, Chi A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastoma
2018
Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma?
Kurz S, Wen P. Quo Vadis—Do Immunotherapies Have a Role in Glioblastoma? Current Treatment Options In Neurology 2018, 20: 14. PMID: 29666934, DOI: 10.1007/s11940-018-0499-0.Peer-Reviewed Original ResearchImmunotherapeutic strategiesSafety of CAR-T cell therapyCAR-T cell therapyT cells in vivoChallenges of immunotherapyCAR-T cellsT-cell therapySuccess of immunotherapyHigh-grade gliomasStudy evaluated treatmentIncreased polyclonalityDC vaccinesDiagnosed glioblastomaImmunotherapy researchRecurrent glioblastomaT cellsImmunotherapyEffective therapyClinical evidenceClinical studiesClinical trialsGlioblastoma microenvironmentGlioblastomaPatientsTherapy